Case report: a R0 resection successfully induced by T-DXd plus PD-1 inhibitor regimen in a primary unresectable stage IIIB NSCLC with ERBB2-mutation
Abstract Chemoradiotherapy (CRT) with consolidative immunotherapy(IO) remains the standard care for unresectable stage III NSCLC, yet survival remains suboptimal in molecular subgroups. Emerging targeted therapies offer the potential for converting unresectable cases to resectable status. We present...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-06-01
|
| Series: | npj Precision Oncology |
| Online Access: | https://doi.org/10.1038/s41698-025-00982-x |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Abstract Chemoradiotherapy (CRT) with consolidative immunotherapy(IO) remains the standard care for unresectable stage III NSCLC, yet survival remains suboptimal in molecular subgroups. Emerging targeted therapies offer the potential for converting unresectable cases to resectable status. We present a 54-year-old female with stage IIIB (T1cN3M0) ERBB2 exon 20-mutated lung adenocarcinoma (PD-L1 50%) and supraclavicular metastasis. After three cycles of ERBB2-targeted antibody-drug conjugate combined with programmed death-1 (PD-1) inhibitor, transient Grade 1 interstitial lung disease resolved with steroids. Serial imaging revealed 58% tumor regression, enabling successful R0 resection via VATS lobectomy with lymphadenectomy. Histopathological analysis confirmed complete pathological response in primary and nodal lesions, corroborated by undetectable postoperative minimal residual disease. The patient remained recurrence-free at a 9-month follow-up. This induction targeted-IO strategy enabled surgical conversion in ERBB2-mutant NSCLC with durable remission and acceptable toxicity, warranting investigation in molecular subgroups with limited CRT-IO benefit. |
|---|---|
| ISSN: | 2397-768X |